Thus, targeting mutant p53 by APR-246 restoring its tumor suppressive function seems to be an effective therapeutic strategy for this high-risk group of TP53 mutant acute lymphoblastic leukemia.
Bone marrow aspirates from 30 children with a diagnosis of acute lymphoblastic leukemia were assessed for the expression of messenger RNA for the MDR-1, MRP and LRP genes by semi-quantitative RT-PCR.